SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-17-024927
Filing Date
2017-12-14
Accepted
2017-12-14 16:01:51
Documents
8
Period of Report
2017-12-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fate-8k_20171212.htm 8-K 46984
2 EX-1.1 fate-ex11_6.htm EX-1.1 247065
3 EX-5.1 fate-ex51_7.htm EX-5.1 13412
4 EX-99.1 fate-ex991_83.htm EX-99.1 11762
5 EX-99.2 fate-ex992_84.htm EX-99.2 11166
6 GRAPHIC g201712141621061933444.jpg GRAPHIC 3659
7 GRAPHIC g201712141621180204381.jpg GRAPHIC 25886
8 GRAPHIC g201712141621298874381.jpg GRAPHIC 3659
  Complete submission text file 0001564590-17-024927.txt   377816
Mailing Address 3535 GENERAL ATOMICS COURT SUITE 200 SAN DIEGO CA 92121
Business Address 3535 GENERAL ATOMICS COURT SUITE 200 SAN DIEGO CA 92121 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36076 | Film No.: 171256179
SIC: 2836 Biological Products, (No Diagnostic Substances)